Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 11.55 USD -2.28%
Market Cap: 2.5B USD

Ocular Therapeutix Inc
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ocular Therapeutix Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Ocular Therapeutix Inc
NASDAQ:OCUL
Gross Profit
$49.6m
CAGR 3-Years
3%
CAGR 5-Years
38%
CAGR 10-Years
41%
Johnson & Johnson
NYSE:JNJ
Gross Profit
$62.8B
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Gross Profit
$35.1B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Gross Profit
$47.1B
CAGR 3-Years
-10%
CAGR 5-Years
7%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Gross Profit
$50.6B
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Gross Profit
$49.3B
CAGR 3-Years
31%
CAGR 5-Years
22%
CAGR 10-Years
13%
No Stocks Found

Ocular Therapeutix Inc
Glance View

Market Cap
2.5B USD
Industry
Pharmaceuticals

Ocular Therapeutix Inc., nestled in the bustling biotechnology hub of Bedford, Massachusetts, is forging a new path in the ophthalmic treatment landscape. At its core, the company's mission pivots on the innovation and commercialization of novel therapies that address significant unmet needs in eye care. By leveraging its proprietary hydrogel technology, Ocular Therapeutix has developed a rich pipeline of both drug delivery and ophthalmic surgical products. Its flagship product, DEXTENZA, stands as a beacon of its innovative approach, offering an alternative to traditional drug delivery methods by releasing medication directly to the target site through a bioresorbable hydrogel implant. This targeted drug delivery not only enhances treatment efficacy but also addresses the age-old challenge of patient compliance in eye care, providing a significant competitive advantage in the market. Financially, Ocular Therapeutix develops its sustainability through a multi-pronged strategy that involves direct sales, licensing agreements, and strategic partnerships. Revenue is primarily generated from sales of its marketed products and milestones achieved through partnerships with other pharmaceutical companies. DEXTENZA and the upcoming products from its pipeline continue to chart new territory in securing market share by offering superior clinical outcomes. The company’s innovative technologies also open doors for licensing deals, providing a steady revenue stream as they partner with global firms that recognize the potential of personalized ophthalmic care. By threading together scientific innovation, strategic commercialization, and robust industry partnerships, Ocular Therapeutix positions itself not just as a biotech company, but as a transformative player aiming to redefine the ophthalmic treatment paradigm.

OCUL Intrinsic Value
1.44 USD
Overvaluation 88%
Intrinsic Value
Price

See Also

What is Ocular Therapeutix Inc's Gross Profit?
Gross Profit
49.6m USD

Based on the financial report for Sep 30, 2025, Ocular Therapeutix Inc's Gross Profit amounts to 49.6m USD.

What is Ocular Therapeutix Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
41%

Over the last year, the Gross Profit growth was -11%. The average annual Gross Profit growth rates for Ocular Therapeutix Inc have been 3% over the past three years , 38% over the past five years , and 41% over the past ten years .

Back to Top